Live Analyst Rating Changes 22588 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gavin Clark-Gartner
EVR

Gavin Clark-Gartner

Evercore ISI
Wall Street Analyst
★★★★☆
#532
on 13Foresight · ranked by our own returns
67%
Success Rate
+18.5%
Average Return
35 of 52 calls profitable · +11.4% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Gavin Clark-Gartner's ratings turned a profit when each position was held for 1 year — averaging +18.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

118 Buy 28 Hold 0 Sell
Gavin's Stock Coverage 32 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ABBV
AbbVie
 Aug 10, 2026 BUY Strong Buy
-3.4% avg upside
46 analysts
$260.00
4.79% Upside
 +0.9% ·
EVMN
Evommune, Inc.
 Aug 10, 2026 BUY Strong Buy
+171.0% avg upside
12 analysts
$22.00
56.37% Upside
 +1.0% ·
CMPS
COMPASS Pathways
 Aug 10, 2026 BUY Strong Buy
+67.7% avg upside
20 analysts
$21.00
59.37% Upside
 +1.5% ·
DNTH
Dianthus Therapeutics
 Aug 10, 2026 BUY Strong Buy
-11.6% avg upside
29 analysts
$134.00
19.82% Upside
 +0.0% ·
TENX
Tenax Therapeutics
 Aug 10, 2026 HOLD Strong Buy
+2253.9% avg upside
9 analysts
$5.00
263.68% Upside
 · ·
VRDN
Viridian Therapeutics
 Aug 10, 2026 BUY Strong Buy
+51.5% avg upside
32 analysts
$26.00
12.76% Upside
 -0.4% ·
RARE
Ultragenyx Pharmaceutical
 Aug 10, 2026 BUY Strong Buy
+150.6% avg upside
36 analysts
$33.00
23.13% Upside
 +0.6% ·
TVTX
Travere Therapeutics
 Aug 10, 2026 BUY Strong Buy
-8.0% avg upside
22 analysts
$78.00
28.04% Upside
 +1.2% ·
SRPT
Sarepta Therapeutics
 Aug 10, 2026 HOLD Buy
+250.8% avg upside
49 analysts
$19.00
10.68% Upside
 · ·
ASND
Ascendis Pharma
 Aug 07, 2026 BUY Strong Buy
+8.4% avg upside
24 analysts
$329.00
28.71% Upside
 -0.6% ·
INSM
Insmed
 Aug 07, 2026 BUY Strong Buy
+32.6% avg upside
37 analysts
$170.00
26.16% Upside
 +2.7% ·
FBRX
Forte Biosciences
 Jul 27, 2026 HOLD Buy
-35.4% avg upside
15 analysts
$77.00
0.29% Upside
 +0.4% ·
DYN
Dyne Therapeutics
 Jul 27, 2026 BUY Strong Buy
+50.9% avg upside
31 analysts
$33.00
24.52% Upside
 +3.4% ·
ARGX
Argenx Se
 Jul 27, 2026 BUY Strong Buy
-9.8% avg upside
47 analysts
$1059.00
22.27% Upside
 -2.7% ·
VERA
Vera Therapeutics
 Jul 09, 2026 BUY Strong Buy
+122.0% avg upside
19 analysts
$91.00
188.17% Upside
 -22.5% ·
CRNX
Crinetics Pharmaceuticals
 Jul 08, 2026 HOLD Buy
-7.9% avg upside
21 analysts
$85.00
1.03% Upside
 +0.5% ·
JSPR
Jasper Therapeutics
 Jul 06, 2026 HOLD Strong Buy
+3900.7% avg upside
17 analysts
 — +51.1% ·
RLYB
Rallybio
 Jul 06, 2026 HOLD Buy
+41.6% avg upside
8 analysts
 — +2.8% ·
AVLN
Avalyn Pharma Inc
 May 26, 2026 BUY Strong Buy
+52.0% avg upside
3 analysts
$51.00
47.49% Upside
 +27.0% ·
MIRM
Mirum Pharmaceuticals
 May 07, 2026 BUY Strong Buy
+14.4% avg upside
22 analysts
$138.00
39.91% Upside
 -3.3% ·
KRYS
Krystal Biotech
 May 05, 2026 BUY Strong Buy
-21.8% avg upside
19 analysts
$300.00
9.54% Downside
 +14.6% ·
MGTX
Meiragtx Holdings
 Apr 01, 2026 BUY Strong Buy
+99.4% avg upside
13 analysts
$18.00
38.25% Upside
 +43.1% ·
DMRA
Damora Therapeutics
 Mar 25, 2026 BUY Strong Buy
-2.5% avg upside
20 analysts
$46.00
55.70% Upside
 +19.4% ·
DFTX
Definium Therapeutics
 Mar 02, 2026 BUY Strong Buy
+4.5% avg upside
21 analysts
$26.00
42.37% Downside
 +139.1% ·
BCRX
BioCryst
 Feb 18, 2026 BUY Strong Buy
+87.8% avg upside
24 analysts
$17.00
72.81% Upside
 +29.2% ·
PRQR
ProQR
 Dec 17, 2025 BUY Strong Buy
+521.7% avg upside
18 analysts
$5.00
176.25% Upside
 -12.4% ·
CABA
Cabaletta Bio
 Dec 17, 2025 HOLD Strong Buy
+397.5% avg upside
16 analysts
$4.00
42.82% Upside
 +19.7% ·
SPRO
Spero Therapeutics
 Dec 17, 2025 HOLD Buy
+1002.5% avg upside
12 analysts
$4.00
225.15% Upside
 -45.5% ·
RCKT
Rocket Pharmaceuticals
 Dec 17, 2025 HOLD Buy
+355.1% avg upside
29 analysts
$5.00
37.36% Upside
 +10.4% ·
FHTX
Foghorn Therapeutics
 Dec 20, 2024 BUY Strong Buy
+90.6% avg upside
17 analysts
$18.00
188.54% Upside
 +1.9% ·
CCCC
C4 Therapeutics
 May 30, 2023 BUY Strong Buy
+390.2% avg upside
19 analysts
$10.00
176.15% Upside
 +48.7% ·
INCY
Incyte
 Aug 03, 2022 HOLD Buy
-11.5% avg upside
47 analysts
$78.00
35.90% Downside
 -10.4% ·
🔒 27 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Gavin Clark-Gartner — Frequently Asked Questions
How accurate are Gavin Clark-Gartner's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Gavin's ratings were profitable over a one-year hold, with an average return of +19.1% per rating, or +11.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Gavin ranked on 13Foresight?
Gavin Clark-Gartner is currently ranked #532 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gavin cover?
Gavin most recently has ratings on ABBV, EVMN, CMPS, DNTH, TENX, VRDN, RARE, TVTX, SRPT, ASND, INSM, FBRX and 20 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.